<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01684462</url>
  </required_header>
  <id_info>
    <org_study_id>AL_IIT_01</org_study_id>
    <nct_id>NCT01684462</nct_id>
  </id_info>
  <brief_title>The Efficacy and Safety Study of ALbumin Therapy in Acute Ischemic Stroke</brief_title>
  <acronym>ALbumin</acronym>
  <official_title>A Phase IIB Placebo Comparative, Double Blinded, Randomized, Multi-center Study to Evaluate the Efficacy and Safety of ALbumin Therapy in Acute Ischemic Stroke Patients in Korea.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul St. Mary's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Green Cross Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul St. Mary's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this clinical study, the efficacy and safety of ALbumin is to be evaluated for the&#xD;
      patients occurred within 12 hours of acute ischemic stroke.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      According to the statistics of the cause of death in 2008 by the Statistics Korea, the stroke&#xD;
      was accounted for a large proportion of cause of death among adults, as well as higher&#xD;
      mortality, severe sequelae. These stroke in acute phase showed neurological deterioration&#xD;
      over 50% of the patients after beginning of treatment and the sequelae resulting in that the&#xD;
      nervous tissue was not regenerated is regarded as irreversible changes.&#xD;
&#xD;
      The test group administered 20% albumin based on 1.25g/kg (up to 100g (500ml) over 80kg body&#xD;
      weight) to the patients occurred within 12 hours of the onset of symptoms and equal amount of&#xD;
      placebo (saline solution (0.9% normal saline)) administered to the control group will be&#xD;
      compared to evaluate the efficacy and safety of ALbumin for the patients with acute ischemic&#xD;
      stroke.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average change in NIHSS</measure>
    <time_frame>at 14±3days</time_frame>
    <description>Comparison of the average change in NIHSS between the control and ALbumin group at screening(-12h~0days) and 14±3days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>NIHSS Score</measure>
    <time_frame>at 14±3days</time_frame>
    <description>Comparison of NIHSS score between the control and ALbumin group at 14±3days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with improvement by NIHSS</measure>
    <time_frame>at 14±3days</time_frame>
    <description>Comparison of the proportion of patients with improvement in NIHSS over 4 at 14±3days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>modified Rankin Scale(mRS) favorable outcome</measure>
    <time_frame>at 3 months</time_frame>
    <description>Comparison of the global functional outcome on modified Rankin Scale(mRS) at screening(-12h~0days) and 3 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume difference on diffusion MRI</measure>
    <time_frame>at 4 days±1days</time_frame>
    <description>Comparison of the volume difference of cerebral infraction defined by diffusion MRI at 4±1days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrent new ischemic lesions on diffusion MRI</measure>
    <time_frame>at 4±1days</time_frame>
    <description>Comparison of the proportion of patients who appear to be recurrent new ischemic lesions defined by diffusion MRI</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Cerebral Infarction</condition>
  <arm_group>
    <arm_group_label>Human Serum Albumin 20</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Human Serum Albumin 20% 100cc intravenously infused over 4~8h</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.9 % Normal saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Treatment with same volume of normal saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Human Serum Albumin 20</intervention_name>
    <description>Human Serum Albumin 20% 100cc albumin 1.25g/kg up to 100g (500ml) intravenously infused over 4~8h, commencing within 12 hours of stroke onset</description>
    <arm_group_label>Human Serum Albumin 20</arm_group_label>
    <other_name>Human Serum Albumin Injection 20% 100ml Greencross</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.9 % Normal Saline</intervention_name>
    <description>Infusion of 100 mL of 0.9% Normal Saline ( equivalent volume of Albumin ) over 4~8h, commencing within 12 hours of stroke onset</description>
    <arm_group_label>0.9 % Normal saline</arm_group_label>
    <other_name>0.9 % Normal Saline ChoongWae INJ. 100ml</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  At least 18 years of age less than 75 years old&#xD;
&#xD;
          -  Patients who can be administered ALbumin within 12hours of onset of acute ischemic&#xD;
             stroke&#xD;
&#xD;
          -  5 ≤ NIHSS score &lt; 15&#xD;
&#xD;
          -  Patients who are agreed by guardian or legal representative in case that patients have&#xD;
             no ability to join study voluntarily&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Medical history of congestive heart failure or patients who are judged congestive&#xD;
             heart failure on admission.&#xD;
&#xD;
          -  Patients with cardiac edema or pulmonary edema.&#xD;
&#xD;
          -  Medical history of myocardial infarction within the past six months.&#xD;
&#xD;
          -  Patients who have serious aortic stenosis and mitral valve stenosis.&#xD;
&#xD;
          -  Signs or symptoms of acute MI on admission (Serum troponin level ≤0.1 ug/L)&#xD;
&#xD;
          -  Those Who had cardiac surgery.&#xD;
&#xD;
          -  Onset of cerebral infarction within the past three months.&#xD;
&#xD;
          -  Before onset of cerebral infarction, patients who were diagnosed as Historical mRS ≥&#xD;
             2.&#xD;
&#xD;
          -  Patients who received treatment of thrombolysis or who planned for treatment of&#xD;
             thrombolysis.&#xD;
&#xD;
          -  Acute tachyarrhythmia or bradyarrhythmia with hemodynamic instability on admission.&#xD;
&#xD;
          -  Acute or chronic lung disease requiring supplemental O2 therapy on admission&#xD;
&#xD;
          -  Severe anemia (Hb &lt; 8.0)&#xD;
&#xD;
          -  Severe dehydration (defined as decreased skin turgor, dry oral mucous membrane,&#xD;
             tachycardia(&gt;100/min), and oliguria)&#xD;
&#xD;
          -  Fever, defined as core body temperature&gt;37.5 ℃&#xD;
&#xD;
          -  Serum creatinine &gt; 2.0 mg/dL&#xD;
&#xD;
          -  History of allergy to albumin.&#xD;
&#xD;
          -  Patients who have side effects of albumin (hyperergia to shock, fever, facial&#xD;
             flushing,urticarial, algor, lumbodynia)&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Patients who are in life-threatening or stupor coma situation.&#xD;
&#xD;
          -  Evidence of intracranial hemorrhage (intracerebral hematoma (ICH), subarachnoid&#xD;
             hemorrhage (SAH), epidural hemorrhage, acute or chronic subdural hematoma (SDH)) on&#xD;
             admission CT or MRI scan.&#xD;
&#xD;
          -  Patients who are not the normal, excesses of circulating blood.&#xD;
&#xD;
          -  Haemolytic anemia, anemia due to blood loss.&#xD;
&#xD;
          -  Immunodeficiency disease, immunosuppression.&#xD;
&#xD;
          -  Blood pressure higher than 180/110 mmHg on admission.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kwang Soo Lee, M.D, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul St. Mary's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Vincent's hospital</name>
      <address>
        <city>Suwon</city>
        <state>Gyeonggido</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ewha Womans University Mokdong Hospital</name>
      <address>
        <city>Mok-dong</city>
        <state>Seoul</state>
        <zip>158-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul St. Mary's Hospital</name>
      <address>
        <city>Seocho-Gu</city>
        <state>Seoul</state>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yeoudo St. Mary's hospital</name>
      <address>
        <city>Yeongdeungpo-Gu</city>
        <state>Seoul</state>
        <zip>150-713</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <study_first_submitted>August 21, 2012</study_first_submitted>
  <study_first_submitted_qc>September 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2012</study_first_posted>
  <last_update_submitted>November 28, 2013</last_update_submitted>
  <last_update_submitted_qc>November 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul St. Mary's Hospital</investigator_affiliation>
    <investigator_full_name>Kwang Soo Lee</investigator_full_name>
    <investigator_title>Neurology Professor</investigator_title>
  </responsible_party>
  <keyword>Acute Ischemic Stroke</keyword>
  <keyword>Albumin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

